https://global-engage.com/assets/topics-BDrtwlA7.js

1var e=[{slug:`ai`,name:`AI`,tagline:`Enterprise AI adoption, safety and leadership.`,description:`From foundation models to production deployment, our AI events convene the leaders scaling AI safely across regulated industries and critical infrastructure.`,highlights:[`Enterprise AI deployment at scale`,`AI governance, safety and assurance`,`Talent, capability and operating models`],overview:[`AI in life sciences has moved past the pilot phase. Foundation models are being fine-tuned on proprietary R&D data, generative chemistry is compressing hit-to-lead timelines, and clinical operations teams are automating protocol design, site selection and safety monitoring. The bottleneck is no longer the model — it's the operating model around it.`,`Global Engage's AI programme is built for the leaders responsible for making this real: heads of computational biology, digital and data officers in pharma and biotech, translational informatics leads, and the regulators shaping how AI-enabled evidence is accepted. Sessions pair peer-reviewed case studies from Roche, GSK, AstraZeneca and Novartis with candid discussion of what didn't work.`,`Expect deep-dive tracks on GxP-grade MLOps, validation frameworks for generative models, prompt and evaluation strategy for regulated environments, and the human capital challenge — how organisations are actually restructuring teams around AI-native ways of working.`],whyItMatters:[`Benchmark your AI operating model against 40+ peer organisations`,`Meet the regulators shaping EMA, FDA and MHRA guidance on AI evidence`,`Leave with concrete validation, governance and MLOps templates`],faqs:[{q:`Who typically attends the AI conferences?`,a:`Heads of computational science, digital and data officers, translational informatics leads, MLOps and platform engineers, plus regulatory strategy leads from pharma, biotech and CROs. Expect a ~70% industry / 30% academia mix.`},{q:`Are the sessions technical or strategic?`,a:`Both. Plenary sessions focus on strategy and operating models; parallel tracks go deep on architecture, validation, evaluation and deployment. Delegates move between tracks depending on the day.`},{q:`Is there a poster or lightning-talk track?`,a:`Yes — most editions include a curated poster session and short-form lightning talks for emerging teams. Submission windows open ~12 weeks before each event.`}]},{slug:`cybersecurity`,name:`Cybersecurity`,tagline:`Resilient infrastru

1cture for a threat-rich era.`,description:`Cybersecurity leadership for a landscape reshaped by AI-driven threats, geopolitics and regulatory pressure — with a focus on Asia's fast-moving digital economies.`,highlights:[`AI-era threat landscape and defence`,`Critical infrastructure resilience`,`Security leadership and the talent gap`],overview:[`The security perimeter that CISOs designed against five years ago no longer exists. AI-assisted intrusion, deepfake-driven social engineering, escalating state-level activity and a fragmenting regulatory landscape have rewritten the risk model — particularly across APAC's fast-moving digital economies.`,`Global Engage's cybersecurity events are convened for enterprise CISOs, heads of security architecture, critical-infrastructure operators and the government agencies coordinating national response. The agenda is deliberately practitioner-led: what actually worked in the last major incident, what didn't, and what boards are now willing to fund.`,`Recurring tracks include AI red-teaming, identity and zero-trust in hybrid estates, third-party and supply-chain risk, incident response playbooks tested in anger, and the leadership challenge of retaining senior security talent in a market where every buyer is competing for the same 200 people.`],whyItMatters:[`Hear post-mortems from the incidents making regional headlines`,`Compare AI red-team tooling and results with 30+ peer CISOs`,`Meet regulators from MAS, MCI, IMDA and equivalent APAC bodies`],faqs:[{q:`Is this a vendor conference?`,a:`No. Speaker slots are reserved for practitioners; sponsors have dedicated exhibition and demo formats rather than main-stage sales pitches. Delegates consistently rate the peer content as the primary reason they return.`},{q:`Do you offer CPE credits?`,a:`Yes — most editions are (ISC)² and ISACA eligible. A signed attendance record is sent to each delegate within 5 working days.`},{q:`Are Chatham House rules in effect?`,a:`Selected roundtables and CISO-only sessions run under Chatham House. Main-stage sessions are recorded and shared with paying delegates only.`}]},{slug:`clinical-trials`,name:`Clinical Trials`,tagline:`Innovation, digital transformation and APAC delivery.`,description:`Where sponsors, CROs and regulators align on the practicalities of running modern clinical trials — with a strong regional lens on the APAC opportunity.`,highlights:[`Digital transformation of trial delivery`,`APAC regulatory and ethical frameworks`,`Sponsor–CRO operating models`],overview:[`The economics of clinical development are under pressure from every direction: rising per-patient costs, complex protocols, and a global patient pool that is more distributed — and more discerning — than ever before. Digital and decentralised trial models are no longer experimental; they are the delivery model for a large share of new studies.`,`Global Engage's clinical trials programme brings sponsor heads of clinical operations, CRO leadership, site networks and APAC regulators together with one aim: to make modern trial delivery practical. Sessions strip out the vendor pitch and focus on operational reality — protocols that recruit, sites that deliver, and data flows that regulators accept.`,`Deep tracks cover decentralised and hybrid trial architecture, APAC regulatory pathways (China NMPA, Japan PMDA, Singapore HSA), risk-based quality management, patient-centric protocol design, and the sponsor–CRO operating models that are actually cutting cycle time rather than just cost.`],whyItMatters:[`Compare notes with sponsors running trials in your therapeutic area`,`Meet APAC regulators face-to-face over two days`,`Take home working templates for RBQM, DCT and CRO governance`],faqs:[{q:`Is the agenda oncology-heavy?`,a:`Oncology is a strong stream but not the only one. Recent editions have carried dedicated content on rare disease, cell & gene therapy, cardiometabolic and vaccine trials.`},{q:`Do regulators actually present?`,a:`Yes. Every recent APAC edition has featured on-stage participation from at least two national regulators, with dedicated Q&A slots.`},{q:`Can CROs attend as delegates?`,a:`Absolutely — a healthy proportion of the room is CRO leadership. Sponsor-only sessions are clearly flagged in the agenda.`}]},{slug:`microbiome`,name:`Microbiome`,tagline:`From ecosystem science to therapeutic pipelines.`,de

1scription:`The microbiome community — R&D leaders, translational scientists and business-development teams — building the next generation of microbiome-informed therapeutics.`,highlights:[`Microbiome and the biological clock`,`Cognition, metabolism and immunity`,`Business development and partnering`],overview:[`Microbiome science has matured from correlation studies to a genuine therapeutic modality. FDA approvals of live biotherapeutic products have unlocked a wave of investment and industrial focus, and the field is now working through the practicalities of manufacturing, delivery, patient stratification and reimbursement at scale.`,`Global Engage's microbiome series — including Probiota Global, Americas and Asia — is the community's principal meeting point. R&D leadership, translational teams, ingredient and platform partners, and the investors backing them share a room for two intense days.`,`The programme spans the gut-brain axis, metabolic and immune indications, next-generation sequencing and multi-omics, live biotherapeutic manufacturing, and the business-development track that has quietly become the industry's default partnering venue.`],whyItMatters:[`The definitive partnering venue for microbiome BD`,`Bench-to-bedside translation with candid post-approval reflection`,`A curated investor track alongside the science`],faqs:[{q:`Is the event more scientific or commercial?`,a:`Both, deliberately. Mornings are typically peer-reviewed science; afternoons split into commercial, BD and clinical translation streams. Delegates report that this mix is the reason they choose Probiota over competing venues.`},{q:`How is partnering organised?`,a:`A structured 1:1 partnering system runs alongside the agenda, with pre-scheduled meetings and dedicated meeting space. Delegates receive access ~4 weeks before the event.`},{q:`Do you cover food and consumer applications?`,a:`Yes — Probiota has always spanned pharmaceutical, medical nutrition and functional food applications, with dedicated tracks for each.`}]},{slug:`spatial-biology`,name:`Spatial Biology`,tagline:`Mapping tissues at single-cell resolution.`,description:`Spatial transcriptomics, proteomics and multi-omics are redefining how translational teams understand disease. Our summits pair platform vendors with the labs putting the technology to work.`,highlights:[`Spatial transcriptomics & proteomics`,`Tumour microenvironment atlases`,`Multi-modal data integration`],overview:[`Spatial biology has become the fastest-moving corner of translational research. In the space of five years, spatial transcriptomics and proteomics have moved from proof-of-concept to core lab workflow — reshaping how translational teams interrogate tumour microenvironments, immune niches and developmental biology.`,`Global Engage's spatial biology summits convene the lab heads generating spatial data, the computational teams making it interpretable, and the platform vendors defining the technology roadmap. The audience is deliberately balanced between academic and industry, and the format prioritises unpublished data and honest platform comparisons.`,`Tracks cover platform selection and benchmarking, panel design for CODEX, MERFISH, Xenium and Visium HD, multi-modal integration with single-cell and bulk data, and the emerging spatial atlases redefining reference biology.`],whyItMatters:[`Unpublished data on the platforms you're about to buy`,`Direct comparisons between the leading spatial vendors`,`A working analytical playbook you can hand to your bioinformatics team`],faqs:[{q:`Which platforms are represented?`,a:`All of them. Recent editions have included content from 10x Genomics, NanoString/Bruker, Vizgen, Akoya, Ionpath and Lunaphore, plus custom in-house pipelines.`},{q:`Is it useful for a wet-lab scientist without a computational background?`,a:`Yes. Tracks are labelled by expected background, and the platform-selection and panel-design content is aimed squarely at wet-lab decision makers.`},{q:`Do you cover clinical-grade spatial workflows?`,a:`Increasingly, yes. Clinical validation and translation to pathology labs is now a dedicated track.`}]},{slug:`single-cell`,name:`Single Cell`,tagline:`Single-cell multi-omics from bench to translation.`,description:`Single-cell technology has moved from novelty to 

1standard tool. Global Engage's single-cell events focus on scale, reproducibility and translational impact.`,highlights:[`Multi-omic single-cell workflows`,`Long-read single-cell sequencing`,`Reference atlases & cell-type nomenclature`],overview:[`Single-cell sequencing is now a standard tool across translational research, but the field's centre of gravity has shifted. The interesting questions are no longer about generating data — they're about scale, reproducibility, integration across sites, and translating findings into clinical hypotheses that hold up.`,`Global Engage's single-cell programme is built for the labs and translational teams working through exactly those questions. Speaker slots are reserved for teams presenting unpublished data or genuine methodological advances; vendor pitches are kept to the exhibition floor.`,`Recurring tracks: multi-omic single-cell workflows (RNA + ATAC + protein), long-read single-cell sequencing, reference cell atlases and cell-type nomenclature, batch correction and integration at cohort scale, and the translational track connecting single-cell insight to drug discovery and clinical biomarker programmes.`],whyItMatters:[`Unpublished data-first agenda`,`Direct engagement with the Human Cell Atlas leadership`,`Practical guidance on scaling single-cell to thousands of samples`],faqs:[{q:`Is this aimed at wet-lab or dry-lab scientists?`,a:`Both. Roughly half the audience is wet-lab, half computational, and the format encourages cross-conversation — most attendees say that's the reason they come.`},{q:`Do you cover spatial single-cell?`,a:`Yes, though the deeper spatial content lives in the Spatial Biology events. Single Cell covers spatial where it intersects with core single-cell workflows.`},{q:`Are there networking dinners?`,a:`Every edition includes a curated speakers' dinner and a wider delegate reception on the first evening.`}]},{slug:`precision-medicine`,name:`Precision Medicine`,tagline:`Biomarkers, companion diagnostics and stratified trials.`,description:`Precision medicine only works when translational science, clinical operations and regulatory teams speak the same language. Our precision medicine events bring them into one room.`,highlights:[`Companion diagnostic co-development`,`Real-world evidence & data platforms`,`Adaptive & basket trial design`],overview:[`Precision medicine is a coordination problem as much as a scientific one. Biomarker discovery, companion diagnostic development, stratified trial design and payer engagement all have to line up — and they typically sit in different functions, sometimes different companies.`,`Global Engage's precision medicine events are convened specifically to close that coordination gap. Translational leads, clinical operations, diagnostic partners, regulators and health-economics teams work through the practicalities together — from biomarker qualification to reimbursement.`,`Deep tracks cover CDx co-development contracts, real-world evidence and data-platform strategy, adaptive and basket trial architecture, patient-selection and enrichment strategies, and the emerging role of AI in biomarker discovery and clinical decision support.`],whyItMatters:[`Diagnostic partners and sponsors in the same room`,`Case studies from recently approved CDx programmes`,`Regulator perspective on companion diagnostic pathways`],faqs:[{q:`Are diagnostics vendors well-represented?`,a:`Yes — this is one of the few venues where CDx developers and pharma sponsors reliably share a room, and the partnering programme reflects that.`},{q:`Do you cover reimbursement and market access?`,a:`Health-economics and market-access content runs as a dedicated stream. Payers and HTA representatives regularly participate.`},{q:`What therapeutic areas are covered?`,a:`Oncology is heaviest, but cardiometabolic, rare disease and CNS all feature. The programme is disease-agnostic where the underlying operating model is transferable.`}]},{slug:`pathology`,name:`Pathology`,tagline:`Digital diagnostics, AI-enhanced histopathology and clinical research.`,description:`From whole-slide imaging to AI-assisted diagnosis, our pathology events explore how digital and computational tools are transforming histopathology, primary diagnosis and translational research.`,highlights:[`Digital pathology and whole-slide imaging`,`AI and machine learning for primary diagnosis`,`Computational pathology in clinical research`],overview:[`Pathology is undergoing its most significant transformation in decades. Whole-slide imaging is now routine in many labs; AI-assisted primary diagnosis is moving from research use to regulated deployment; and computational pathology is unlocking translational biomarkers that were invisible on glass.`,`Global Engage's pathology programme convenes chief pathologists, digital transformation leads, AI vendors and the pharma teams using pathology data to guide translational decisions. The agenda focuses on the operational reality of digital deployment — workflow, validation, storage, and getting reporting pathologists on side.`,`Tracks cover WSI infrastru

1cture and IT integration, AI validation and regulatory frameworks, computational biomarkers for clinical trials, telepathology and cross-site reporting, and the workforce transformation required to make digital pathology routine.`],whyItMatters:[`Practical playbooks from labs already fully digital`,`AI vendors compared side-by-side by the pathologists using them`,`Bridges between anatomic pathology and translational pharma`],faqs:[{q:`Is this a clinical or research event?`,a:`Both. Primary diagnosis, translational research and clinical-trial-enabling pathology are covered on parallel tracks, and cross-over between the two is one of the main reasons delegates value the event.`},{q:`Do AI vendors present clinical evidence?`,a:`Yes, and they are expected to present real validation data — not just marketing claims. The programme committee screens submissions accordingly.`},{q:`Are pathology residents welcome?`,a:`Yes — a discounted residents/early-career rate is available on request.`}]}];function t(t){return e.find(e=>e.slug===t)}export{t as n,e as t};